Eye (London, England) · 2004
Trans-scleral diode laser cyclophoto-coagulation in the treatment of diabetic neovascular glaucoma.
Оценочное исследованиеСтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Dai H-L, Zhou X, Guang X-F
Аннотация
AIMS: To assess efficacy of trans-scleral diode laser cyclophotocoagulation in the treatment of diabetic neovascular glaucoma refractory to medical therapy.
METHODS: Case notes of 20 eyes of 20 patients who had the treatment were analysed. The mean follow-up after initial treatment was 22.5 months (range of 18-24).
RESULTS: Mean (SD) pretreatment intraocular pressure (IOP) for the 20 eyes was 34.4 mmHg (9.5) reducing to 18.2 mmHg (12.4) at the final index visit (P = 0.0001). The mean (SD) number of topical antiglaucoma medication was significantly lowered from 3.9 (0.3) to 1.2 (1.3). Four patients had visual acuity of 6/60 or better before the treatment. Two of them maintained the same level of vision and the other two had their vision reduced over the course of study; however, none of them deteriorated beyond 6/60. Six out of the remaining 16 patients who had vision of counting fingers or worse before treatment progressed to no perception of light at the final index visit. The mean (SD) number of treatment sessions was 1.45 (0.68). A total of 10 patients had previous pars plana vitrectomy (PPV). Patients with two or more PPVs developed hypotony (IOP </=5). There were five eyes with hypotony, one of which became phthisical.
CONCLUSION: Trans-scleral diode laser cyclophotocoagulation is a useful tool in the management of diabetic neovascular glaucoma. The current treatment regime needs to be adjusted to reflect higher risk of hypotony and phthisis in diabetic neovascular glaucoma in eyes that have had multiple pars plana vitrectomies.
METHODS: Case notes of 20 eyes of 20 patients who had the treatment were analysed. The mean follow-up after initial treatment was 22.5 months (range of 18-24).
RESULTS: Mean (SD) pretreatment intraocular pressure (IOP) for the 20 eyes was 34.4 mmHg (9.5) reducing to 18.2 mmHg (12.4) at the final index visit (P = 0.0001). The mean (SD) number of topical antiglaucoma medication was significantly lowered from 3.9 (0.3) to 1.2 (1.3). Four patients had visual acuity of 6/60 or better before the treatment. Two of them maintained the same level of vision and the other two had their vision reduced over the course of study; however, none of them deteriorated beyond 6/60. Six out of the remaining 16 patients who had vision of counting fingers or worse before treatment progressed to no perception of light at the final index visit. The mean (SD) number of treatment sessions was 1.45 (0.68). A total of 10 patients had previous pars plana vitrectomy (PPV). Patients with two or more PPVs developed hypotony (IOP </=5). There were five eyes with hypotony, one of which became phthisical.
CONCLUSION: Trans-scleral diode laser cyclophotocoagulation is a useful tool in the management of diabetic neovascular glaucoma. The current treatment regime needs to be adjusted to reflect higher risk of hypotony and phthisis in diabetic neovascular glaucoma in eyes that have had multiple pars plana vitrectomies.